Question 170
In the next assurance review, the team has started remediation after finding that a pharmaceutical researcher adopts generative AI for unpublished clinical data. Which measurement would be most relevant for judging whether the exposure is reducing?
Explanation
Correct Answer
Measure unapproved AI data destinations and exception rates. New technology introduces data flows beyond existing control assumptions.
Incorrect Answers
Emerging external threats should be evaluated in business dependency terms. This solves “Track critical routes with no independent navigation fallback”; the stated issue is “researcher adopts generative AI for unpublished clinical data”.
Changing attacker methods can invalidate old identity assurance assumptions. The deciding difference is “in account takeover activity using deepfake verification calls” versus “researcher adopts generative AI for unpublished clinical data”.
Supply-chain threats must map to deployed products and customer exposure. Its application is “discovers a long-lived attack path through open-source dependencies”, not the need “researcher adopts generative AI for unpublished clinical data”.